Yoshimi Muta

Imeglimin may improve albuminuria associated with partial suppression of inflammatory and fibrotic markers in diabetic kidney disease

Yoshimi Muta, Hisashi Yokomizo, Takako Kawanami, Yuriko Hamaguchi et autres

Imeglimin is an oral hypoglycemic agent marketed in Japan that has shown glucose-lowering effects in Japanese patients with type 2 diabetes in TIMES trials. However, it is not well known whether imeglimin can affect diabetic kidney disease (DKD). To clarify this, we …

jp, mx (code pays fourni par la source)

Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes

Takaya Matsushita, Yukihiro Wada, Masuo Saburi, Kazuo Kobayashi et autres

jp (code pays fourni par la source)

Fingertip skin autofluorescence as a non‐invasive marker for vascular complications in patients with type 2 diabetes

M. Takeshita, Takeshi Matsumura, Aiko Arimura, Hiroyuki Takahashi et autres

AIMS/INTRODUCTION: This study aimed to investigate whether non-invasive fingertip autofluorescence can evaluate micro- and macrovascular complications in patients with type 2 diabetes. MATERIALS AND METHODS: This multicenter cross-sectional study recruited 452 patients with type 2 diabetes between August 2017 and January 2023. …

jp (code pays fourni par la source)

379-P: Imeglimin May Improve Inflammation and Fibrosis in Diabetic Kidney Disease

Yoshimi Muta, Hisashi Yokomizo, Takako Kawanami, Yuriko Hamaguchi et autres

Introduction and Objective: Imeglimin is an oral hypoglycemic agent marketed from Japan and has shown glucose-lowering effects in Japanese patients with type 2 diabetes in TIMES trials. However, it is not well known whether imeglimin can affect diabetic kidney disease (DKD). To …

Association between self-stigma and diabetic complications in Japanese people with type 2 diabetes: a cross-sectional study

Mayuko Yamamoto, Yuichi Takashi, Masashi Ishizu, Kyoko Toyokawa et autres

OBJECTIVES: To investigate the association between self-stigma evaluated using the Japanese version of the Self-Stigma Scale (SSS-J) and diabetic complications, such as diabetic retinopathy (DR) and diabetic kidney disease (DKD). DESIGN: Cross-sectional study. SETTING: One university hospital and one clinic in Fukuoka, …

jp (code pays fourni par la source)

Liver function effects of SGLT2 inhibitor and GLP ‐1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)

Daisuke Tsuriya, Kazuo Kobayashi, Kei Takeshita, Takuya Hashimoto et autres

AIM: The favor effect on liver disease by odium-glucose cotransporter inhibitor (SGLT2i) and GLP-1 receptor agonist (GLP1Ra) was reported; however, the effect of the combination treatment of these drugs was not well known. METHODS: We retrospectively analyzed data for 643 patients with …

jp (code pays fourni par la source)

Influence of Combination Therapy with Dulaglutide or Liraglutide and SGLT2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Post-hoc Analysis of the RECAP Study.

Yoshimi Muta, Kazuo Kobayashi, Masao Toyoda, Shunichiro Tsukamoto et autres

OBJECTIVE: We report that the effect of combination therapy with SGLT2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1Ra) on renal composite outcomes is not affected by the preceding drug in patients with type 2 diabetes (T2D). In this study, we performed …

jp (code pays fourni par la source)

Two Cases of Tumor-induced Osteomalacia Resulting in Surgical Resection during Burosumab Therapy

Dai Nagata, Yuichi Takashi, Mayuko Yamamoto, Kyoko Toyokawa et autres

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome that results from tumors that secrete fibroblast growth factor 23 (FGF23). This leads to chronic hypophosphatemia. Burosumab, an anti-FGF23 antibody, is an effective treatment when surgery is not possible; however, it complicates FGF23 measurements …

jp (code pays fourni par la source)

Sex Differences in Renal Outcomes and Metabolic Markers by Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Individuals with Type 2 Diabetes: A Post-Hoc Analysis of the RECAP Study

Yoshimi Muta, Kazuo Kobayashi, Masao Toyoda, Mari Sotozawa et autres

Introduction: We previously reported that combination therapy with SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1Ra) was beneficial for the progression of diabetic kidney disease. However, sex differences in renal outcomes and metabolic markers with combination therapy remain unclear. To clarify this, …

jp (code pays fourni par la source)

SGLT2 Inhibitor and GLP-1 Receptor Agonist Co-Treatment: Liver Function Effects in Patients with Type 2 Diabetes Mellitus

Daisuke Tsuriya, Kazuo Kobayashi, Kei Takeshita, Takuya Hashimoto et autres

Abstract Purpose We evaluated the effects of sodium-glucose cotransporter inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP1Ras) combination treatment in patients with type 2 diabetes mellitus (T2DM). Methods We retrospectively analyzed data for 643 patients with T2DM receiving SGLT2i + GLP1Ra combination treatment …

jp (code pays fourni par la source)

Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease

Shunichiro Tsukamoto, Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone et autres

AIM: To conduct a post hoc subgroup analysis of patients with type 2 diabetes (T2D) from the RECAP study, who were treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor and glucagon-like peptide 1 receptor agonist (GLP-1RA) combination therapy, focusing only on those patients who …

jp, us, au (code pays fourni par la source)

Author response for "Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease "

RECAP study group, Shunichiro Tsukamoto, Kazuo Kobayashi, Masao Toyoda et autres